Opinion

Video

When is MRD Testing Performed in Colorectal Cancer Treatment?

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Joseph M. Scandura, MD, PhD, Weill Cornell
Benjamin Adam Weinberg, MD, associate professor, medicine, Georgetown Lombardi Comprehensive Cancer Center
Related Content
John L. Marshall, MD, of Georgetown Lombardi Comprehensive Cancer Center
October 28th 2024

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

John H. Strickler, MD
October 21st 2024

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Kristen K. Ciombor, MD, MSCI
October 11th 2024

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

Todd Aguilera, MD, PhD, assistant professor, radiation oncology, UT Southwestern Medical Center
October 10th 2024

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm